GT Biopharma (GTBP) Revenue (2010 - 2015)

GT Biopharma (GTBP) posted quarterly Revenue of $20000.0 for Q2 2015, up 185.71% quarter-over-quarter from $7000.0 in Q1 2015.

GT Biopharma (GTBP) Revenue (2010 - 2015) Analysis & Trends

GT Biopharma (GTBP) has reported Revenue for 5 consecutive years, with $20000.0 the latest figure, recorded in Q2 2015.

In Q2 2015, Revenue changed N/A year-over-year to $20000.0; the TTM figure through Mar 2016 stood at $20000.0 (up 171.43% YoY), while the FY2015 annual figure was $27000.0, down 3.57% from the prior year.
Revenue advanced to $20000.0 in Q2 2015 per GTBP's latest filing, from $7000.0 in the prior quarter.
Across five years, Revenue topped out at $120000.0 in Q3 2012 and bottomed at -$123000.0 in Q4 2012.
Historically, Revenue has averaged $12727.3 across 4 years, with a median of $3000.0 in 2011.
Annual changes were most pronounced in 2012 — Revenue tumbled 4200.0% — and 2013, when it jumped 8700.0%.
GT Biopharma's Revenue stood at $3000.0 in 2011, then sank by 4200.0% to -$123000.0 in 2012, then surged by 171.54% to $88000.0 in 2013, then plunged by 77.27% to $20000.0 in 2015.
Business Quant data shows GTBP's Revenue at $20000.0 in Q2 2015, $7000.0 in Q1 2015, and $88000.0 in Q1 2013.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	3.33 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	4.29 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	1.52 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	145.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	1.71 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	1.29 Bn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	1.06 Bn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	425.49 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	674.14 Mn
10	GT Biopharma	8.64 Mn	8.64 Mn	-	-

Download Data